Benchmark initiated coverage of Kamada (KMDA) with a Buy rating and $15 price target Kamada has expanded its specialty plasma-derived product line through acquisitions and organic growth over the past several years, the analyst tells investors. Benchmark expects an active R&D pipeline and recently opened plasma-collection facilities to continue to drive double digit revenue growth and expanding margins.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMDA:
- Kamada initiated with a Buy at Benchmark
- Kamada Expands Plasma Collection Operations with New San Antonio Center
- Kamada opens third plasma collection center in San Antonio, Texas
- Kamada: A Growth-Oriented Investment with Strong Financials and Strategic Expansion Plans
- Kamada Ltd’s Growth at Risk: Manufacturing Capacity and Expansion Challenges Loom Large